(Q42250772)

English

Extent of HCV NS3 protease variability and resistance-associated mutations assessed by next generation sequencing in HCV monoinfected and HIV/HCV coinfected patients

scientific article published on 13 August 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Extent of HCV NS3 protease variability and resistance-associated mutations assessed by next generation sequencing in HCV monoinfected and HIV/HCV coinfected patients (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Gabriella Rozera

5

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Giuseppe Ippolito

8

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Maria Rosaria Capobianchi

10

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

object named as

Marina Selleri

4

0 references

Isabella Abbate

6

object named as

Isabella Abbate

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

author name string

Barbara Bartolini

1

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Emanuela Giombini

2

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Paola Zaccaro

3

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Ubaldo Visco Comandini

7

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

Mariacarmela Solmone

9

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

13 August 2013

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

177

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

205-208

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

describes a project that uses

massive parallel sequencing

1 reference

based on heuristic

inferred from title

Detection of quasispecies variants predicted to use CXCR4 by ultra-deep pyrosequencing during early HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2013.08.001

7 January 2021

A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2013.08.001

7 January 2021

The presence of resistance mutations to protease and polymerase inhibitors in Hepatitis C virus sequences from the Los Alamos databank

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2013.08.001

7 January 2021

Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2013.08.001

7 January 2021

HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2013.08.001

7 January 2021

Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2013.08.001

7 January 2021

Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2013.08.001

7 January 2021

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2013.08.001

7 January 2021

Detection of hepatitis C mutants with natural resistance to NS3/4A protease inhibitors in HIV/HCV-coinfected individuals treated with antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2013.08.001

7 January 2021

Whole genome pyrosequencing of rare hepatitis C virus genotypes enhances subtype classification and identification of naturally occurring drug resistance variants.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2013.08.001

7 January 2021

Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2013.08.001

7 January 2021

Rapid emergence of protease inhibitor resistance in hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2013.08.001

7 January 2021

Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2013.08.001

7 January 2021

Selection of Replicon Variants Resistant to ACH-806, a Novel Hepatitis C Virus Inhibitor with No Cross-Resistance to NS3 Protease and NS5B Polymerase Inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2013.08.001

7 January 2021

Identifiers

10.1016/J.VIRUSRES.2013.08.001

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42250772&oldid=1940126041"